

27 November 2019

ASX Code: MXC

MGC Pharma AGM Webinar

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), is pleased to announce it will be hosting an Annual General Meeting (AGM) webinar on **Friday 29 November at 2:00pm AWST.**

The formal business of the AGM will be hosted by MGC Pharma's Chairman, Brett Mitchell, followed by a presentation (released 14 November 2019) to be presented by the Company's Managing Director, Roby Zomer.

To register for the webinar, please use the link below:

https://zoom.us/webinar/register/WN_eOC4NpA1Rdi11rj-JZ-POA

Upon registration participants will be able to submit questions to the Company. The Board will endeavour to answer as many questions as possible regarding the Company's operations and future plans at the meeting.

--Ends--

For further information, please contact:

UK IR/Media Advisors

Catherine Leftley/Megan Dennison

St Brides Partners Ltd

+44 (0) 207 236 1177

megan@stbridespartners.co.uk

catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting three widespread medical conditions - epilepsy, dementia and IBS – and has further products in the development pipeline.

Employing its 'Seed to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia and the UK and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m² GMP state of the art facility in Malta.

Follow us through our social media channels

